EMPLOYMENT AGREEMENTEmployment Agreement • February 27th, 2015 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”), dated as of February 24, 2015, is entered into by and between Merrimack Pharmaceuticals, Inc., a Delaware corporation with a place of business at One Kendall Square, Suite B7201, Cambridge, Massachusetts 02139 (the “Company”), and Peter N. Laivins, an individual residing at 22 Bridle Lane, Scituate, MA 02066 (the “Employee”).
FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • February 27th, 2015 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations
THIS FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is dated as of February 25, 2015 (the “Fourth Amendment Date”), and is effective as of February 1, 2015, and is entered into by between MERRIMACK PHARMACEUTICALS, INC., a Delaware corporation, and each of its Subsidiaries that from time to time becomes a party hereto (hereinafter collectively referred to as “Borrower”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation (“Lender”).
THIRD AMENDMENT OF LEASELease • February 27th, 2015 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations
THIS THIRD AMENDMENT OF LEASE (this “Amendment”) is made as of this 23rd day of February, 2015 (the “Execution Date”), by and between DWF IV ONE KENDALL, LLC, a Delaware limited liability company having an address c/o Divco West Real Estate Services, Inc., One Kendall Square, Cambridge, MA 02139, Attention: Property Manager (“Landlord”) and MERRIMACK PHARMACEUTICALS, INC., a Delaware corporation having a mailing address at One Kendall Square, Building 600/700, Cambridge, MA 02139 (“Tenant”).
FIRST AMENDMENT TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENTDevelopment, License and Supply Agreement • February 27th, 2015 • Merrimack Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS FIRST AMENDMENT TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this “Amendment”) is made and entered into as of the latest dated signature on the signature page hereto, and is by and between Watson Laboratories, Inc., a Nevada corporation (“Actavis”), on the one hand, and Merrimack Pharmaceuticals, Inc., a Delaware corporation (“Merrimack”), on the other hand. Actavis and Merrimack shall be referred to herein collectively as the “Parties.”
